Parkinson Disease

>

The NeurologyLive® Parkinson disease Disease Spotlight page gives readers key updates and detailed coverage on the most recent expert conversations and data presentations relevant to the treatment of the movement disorder.

Latest News

FDA Issues Complete Response Letter for Apomorphine Infusion Device SPN-830 in Parkinson Disease Treatment
FDA Issues Complete Response Letter for Apomorphine Infusion Device SPN-830 in Parkinson Disease Treatment

April 8th 2024

SPN-830, an apomorphine infusion device, had its new drug application submitted using data from the phase 3 TOLEDO trial.

Lasse Pihlstrøm, PhD, senior researcher in department of neurology at Oslo University Hospital in Norway
Lysosomal Pathway Significantly Impacts Cognitive Decline Progression in Parkinson Disease With Low Alzheimer Risk

April 4th 2024

Olivier Rascol, MD, PhD
Potential Safety Concerns With Lixisenatide Despite Showing Slowed Motor Disability Progression in Phase 2 Trial for Early Parkinson Disease

April 4th 2024

NKCC1 Inhibitor Bumetanide Shows No Effect on Parkinson Disease Progression
NKCC1 Inhibitor Bumetanide Shows No Effect on Parkinson Disease Progression

March 30th 2024

Exposure to Trichloroethylene Linked With Increased Risk of Parkinson Disease, Cancer
Exposure to Trichloroethylene Linked With Increased Risk of Parkinson Disease, Cancer

March 29th 2024

Video Interviews
Podcasts

More News

© 2024 MJH Life Sciences

All rights reserved.